Funding for this research was provided by:
National Institute of Dental and Craniofacial Research (Grant No. K12DE023574)
Received: 8 February 2021
Accepted: 26 December 2021
First Online: 11 January 2022
: All procedures and surveys for this anonymous, confidential survey study were approved as an exempt study by the Institutional Review Board at the University of Michigan under protocol HUM00079294.
: Not applicable
: Drs. Yakas, DeJonckheere, Williams and Goesling, and Mr. Scott declare no conflicts of interest. Dr. Boehnke sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). Dr. Clauw has consulted for Pfizer, Inc, Eli Lilly and Company, Tonix Pharmaceuticals, Aptinyx, Regeneron, IMC, and Intec. Dr. Litinas is Chief Medical Officer at and co-owner of Om of Medicine, a medical cannabis provisioning center in Ann Arbor, MI. Dr. Sisley leads the Scottsdale Research Institute, has received funding from the Multidisciplinary Association for Psychedelic Studies and is a member of the Steering Committee/Entrepreneurship and Social Initiative Impact Advisor Board for the Lambert Center for the Study of Medicinal Cannabis and Hemp.